{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:08:37Z","timestamp":1792112917044,"version":"4.4.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40263-024-01078-z","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T07:02:30Z","timestamp":1710831750000},"page":"239-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-4024","authenticated-orcid":false,"given":"Nora","family":"Vanegas-Arroyave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley N.","family":"Caroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovita","family":"Crasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khody","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Manahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"1078_CR1","unstructured":"Stagnitti MN. Trends in antipsychotics purchases and expenses for the U.S. civilian noninstitutionalized population, 1997 and 2007. Statistical Brief #275. Agency for Healthcare Research and Quality, Rockville, MD. 2010."},{"key":"1078_CR2","unstructured":"Ahrnsbra R, Stagnitti MN. Comparision of antidepressant and antipsychotic utilization and expenditures in the U.S. civilian noninstitutionalized population, 2013 and 2018. Statistical Brief #534. Agency for Healthcare Research and Quality, Rockville, MD. 2021."},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18\u201328.","journal-title":"Schizophr Res"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cnur.2019.08.004","volume":"54","author":"S Dilks","year":"2019","unstructured":"Dilks S, Xavier RM, Kelly C, Johnson J. Implications of antipsychotic use: antipsychotic-induced movement disorders, with a focus on tardive dyskinesia. Nurs Clin N Am. 2019;54:595\u2013608.","journal-title":"Nurs Clin N Am"},{"key":"1078_CR5","first-page":"CD013304","volume":"12","author":"V Muhlbauer","year":"2021","unstructured":"Muhlbauer V, Mohler R, Dichter MN, Zuidema SU, Kopke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer\u2019s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12:CD013304.","journal-title":"Cochrane Database Syst Rev"},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/WCO.0000000000001199","volume":"36","author":"DP Devanand","year":"2023","unstructured":"Devanand DP. Management of neuropsychiatric symptoms in dementia. Curr Opin Neurol. 2023;36:498\u2013503.","journal-title":"Curr Opin Neurol"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.11.004","volume":"82","author":"TSJ Iversen","year":"2018","unstructured":"Iversen TSJ, Steen NE, Dieset I, Hope S, M\u00f8rch R, Gardsjord ES, et al. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263\u201371.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-023-01022-7","volume":"37","author":"JM Meyer","year":"2023","unstructured":"Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia. CNS Drugs. 2023;37:545\u201370.","journal-title":"CNS Drugs"},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1017\/S109285292000200X","volume":"27","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27:208\u201317.","journal-title":"CNS Spectr"},{"key":"1078_CR10","doi-asserted-by":"crossref","unstructured":"Chepke C, Benning B, Cicero S, Hull M, Giraldo E, Yeaw J, et al. Investigating real-world benztropine usage patterns in movement disorders: claims analysis and health care provider survey results. Prim Care Companion CNS Disord. 2023;25:22m03472.","DOI":"10.4088\/PCC.22m03472"},{"key":"1078_CR11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615371624","volume-title":"The American Psychiatric Association Publishing textbook of psychopharmacology","author":"AF Schatzberg","year":"2017","unstructured":"Schatzberg AF, Nemeroff CB, American Psychiatric Association. The American Psychiatric Association Publishing textbook of psychopharmacology. 5th ed. Arlington: American Psychiatric Association Publishing; 2017.","edition":"5"},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","volume":"43","author":"SE Yohn","year":"2022","unstructured":"Yohn SE, Weiden PJ, Felder CC, Stahl SM. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43:1098\u2013112.","journal-title":"Trends Pharmacol Sci"},{"key":"1078_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.609005","volume":"14","author":"TNT Ho","year":"2020","unstructured":"Ho TNT, Abraham N, Lewis RJ. Structure-function of neuronal nicotinic acetylcholine receptor inhibitors derived from natural toxins. Front Neurosci. 2020;14: 609005.","journal-title":"Front Neurosci"},{"key":"1078_CR14","first-page":"39","volume":"2","author":"DR Brocks","year":"1999","unstructured":"Brocks DR. Anticholinergic drugs used in Parkinson\u2019s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999;2:39\u201346.","journal-title":"J Pharm Pharm Sci"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1755-5949.2010.00142.x","volume":"16","author":"DB Lester","year":"2010","unstructured":"Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16:137\u201362.","journal-title":"CNS Neurosci Ther"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2019.02.019","volume":"126","author":"S Ztaou","year":"2019","unstructured":"Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson\u2019s disease. Neurochem Int. 2019;126:1\u201310.","journal-title":"Neurochem Int"},{"key":"1078_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuroscience.2021.05.026","volume":"467","author":"RM Paz","year":"2021","unstructured":"Paz RM, Murer MG. Mechanisms of antiparkinsonian anticholinergic therapy revisited. Neuroscience. 2021;467:201\u201317.","journal-title":"Neuroscience"},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","volume":"7","author":"KM Ward","year":"2018","unstructured":"Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia - Key differences in pathophysiology and clinical management. Neurol Ther. 2018;7:233\u201348.","journal-title":"Neurol Ther."},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuron.2016.06.014","volume":"91","author":"G Kharkwal","year":"2016","unstructured":"Kharkwal G, Brami-Cherrier K, Lizardi-Ortiz JE, Nelson AB, Ramos M, Del Barrio D, et al. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron. 2016;91:67\u201378.","journal-title":"Neuron"},{"key":"1078_CR20","doi-asserted-by":"publisher","first-page":"204512532211173","DOI":"10.1177\/20451253221117313","volume":"12","author":"H Takeuchi","year":"2022","unstructured":"Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Ther Adv Psychopharmacol. 2022;12:20451253221117310.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1017\/S1092852912000752","volume":"18","author":"AJ Loonen","year":"2013","unstructured":"Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15\u201320.","journal-title":"CNS Spectr"},{"key":"1078_CR22","first-page":"Cd000204","volume":"1","author":"H Bergman","year":"2018","unstructured":"Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:Cd000204.","journal-title":"Cochrane Database Syst Rev"},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","volume":"81","author":"R Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463\u20139.","journal-title":"Neurology"},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/jnnp.37.8.941","volume":"37","author":"HL Klawans","year":"1974","unstructured":"Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974;37:941\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1192\/bjp.145.3.304","volume":"145","author":"W Greil","year":"1984","unstructured":"Greil W, Haag H, Rossnagl G, R\u00fcther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984;145:304\u201310.","journal-title":"Br J Psychiatry"},{"key":"1078_CR26","first-page":"233","volume":"14 Spec No","author":"R Yassa","year":"1988","unstructured":"Yassa R. Tardive dyskinesia and anticholinergic drugs. A critical review of the literature. L\u2019Encephale. 1988;14 Spec No:233\u20139.","journal-title":"L'Encephale."},{"key":"1078_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/schbul\/23.4.583","volume":"23","author":"MF Egan","year":"1997","unstructured":"Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23:583\u2013609.","journal-title":"Schizophr Bull"},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1517\/14740338.2016.1165664","volume":"15","author":"PS Nishtala","year":"2016","unstructured":"Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf. 2016;15:753\u201368.","journal-title":"Expert Opin Drug Saf"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/mdc3.13347","volume":"8","author":"MJ Barrett","year":"2021","unstructured":"Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8:1181\u20138.","journal-title":"Mov Disord Clin Pract."},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.psc.2016.04.003","volume":"39","author":"SN Caroff","year":"2016","unstructured":"Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatric Clin North Am. 2016;39:391\u2013411.","journal-title":"Psychiatric Clin North Am."},{"key":"1078_CR31","first-page":"198","volume":"32","author":"SN Caroff","year":"2020","unstructured":"Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020;32:198\u2013208.","journal-title":"Ann Clin Psychiatry"},{"key":"1078_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.chest.2023.08.014","volume":"164","author":"J Bourbeau","year":"2023","unstructured":"Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelly SB, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164:1159\u201383.","journal-title":"Chest"},{"key":"1078_CR33","first-page":"CD012066","volume":"6","author":"N Fukuda","year":"2023","unstructured":"Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023;6:CD012066.","journal-title":"Cochrane Database Syst Rev"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00192-019-04022-8","volume":"30","author":"FC Hsu","year":"2019","unstructured":"Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019;30:1603\u201317.","journal-title":"Int Urogynecol J"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","volume":"8","author":"H Mostafaei","year":"2022","unstructured":"Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, et al. Choosing the most efficacious and safe orl teatment for iiopathic oeractive badder: a systematic review and network meta-analysis. Eur Urol Focus. 2022;8:1072\u201389.","journal-title":"Eur Urol Focus"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1517\/14740338.2011.579899","volume":"10","author":"P Gerretsen","year":"2011","unstructured":"Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10:751\u201365.","journal-title":"Expert Opin Drug Saf"},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717\u201326.","journal-title":"N Engl J Med"},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400:2210\u201320.","journal-title":"Lancet"},{"key":"1078_CR39","doi-asserted-by":"publisher","DOI":"10.1017\/9781108975292","volume-title":"Stahl's essential psychopharmacology: neuroscientific basis and practical applications","author":"SM Stahl","year":"2021","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications. 5th ed. Cambridge: Cambridge University Press; 2021.","edition":"5"},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bcp.12839","volume":"81","author":"AH Dawson","year":"2016","unstructured":"Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol. 2016;81:516\u201324.","journal-title":"Br J Clin Pharmacol"},{"key":"1078_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/15563650.2020.1854281","volume":"59","author":"GS Wang","year":"2021","unstructured":"Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila). 2021;59:698\u2013704.","journal-title":"Clin Toxicol (Phila)"},{"issue":"Suppl 21","key":"1078_CR42","first-page":"11","volume":"62","author":"LE Tune","year":"2001","unstructured":"Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11\u20134.","journal-title":"J Clin Psychiatry"},{"key":"1078_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.779607","volume":"12","author":"R Georgiou","year":"2021","unstructured":"Georgiou R, Lamnisos D, Giannakou K. Anticholinergic burden and cognitive performance in patients with schizophrenia: a systematic literature review. Front Psychiatry. 2021;12: 779607.","journal-title":"Front Psychiatry."},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ajp.2019.10.013","volume":"46","author":"SJ Kim","year":"2019","unstructured":"Kim SJ, Jung D, Shim JC, Moon JJ, Jeon DW, Kim YN, et al. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. Asian J Psychiatr. 2019;46:111\u20137.","journal-title":"Asian J Psychiatr"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","volume":"166","author":"S Vinogradov","year":"2009","unstructured":"Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055\u201362.","journal-title":"Am J Psychiatry"},{"key":"1078_CR46","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73:721\u201332.","journal-title":"JAMA Neurol"},{"key":"1078_CR47","doi-asserted-by":"crossref","unstructured":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021.","DOI":"10.1176\/appi.books.9780890424841"},{"key":"1078_CR48","unstructured":"Osmolex ER (amantadine) extended-release tablets. Prescribing information. Emeryville, CA: Adamas Pharma, LLC; 2021."},{"key":"1078_CR49","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.4088\/JCP.v69n1204","volume":"69","author":"TD Satterthwaite","year":"2008","unstructured":"Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69:1869\u201379.","journal-title":"J Clin Psychiatry"},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.4088\/JCP.v68n1207","volume":"68","author":"L Citrome","year":"2007","unstructured":"Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68:1876\u201385.","journal-title":"J Clin Psychiatry"},{"key":"1078_CR51","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1007\/s12325-022-02274-3","volume":"39","author":"L Citrome","year":"2022","unstructured":"Citrome L, Risinger R, Rajachandran L, Robison H. Sublingual dexmedetomidine for agitation associated with schizophrenia or bipolar disorder: a post hoc analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Adv Ther. 2022;39:4821\u201335.","journal-title":"Adv Ther"},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","volume":"32","author":"RE Burke","year":"1982","unstructured":"Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32:1335\u201346.","journal-title":"Neurology"},{"key":"1078_CR53","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/brain\/121.11.2053","volume":"121","author":"V Kiriakakis","year":"1998","unstructured":"Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121:2053\u201366.","journal-title":"Brain"},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0006-3223(98)00242-X","volume":"45","author":"Adityanjee","year":"1999","unstructured":"Adityanjee, Aderibigbe YA, Jampala VC, Mathews T. The current status of tardive dystonia. Biol Psychiatry. 1999;45:715\u201330.","journal-title":"Biol Psychiatry"},{"key":"1078_CR55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10072-022-06506-w","volume":"44","author":"M Grabel","year":"2023","unstructured":"Grabel M, Merola A. Pallidal deep brain stimulation for tardive dystonia: meta-analysis of clinical outcomes. Neurol Sci. 2023;44:827\u201333.","journal-title":"Neurol Sci"},{"key":"1078_CR56","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2174\/1570159X14666161208153644","volume":"15","author":"H Salem","year":"2017","unstructured":"Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017;15:789\u201398.","journal-title":"Curr Neuropharmacol"},{"key":"1078_CR57","doi-asserted-by":"crossref","unstructured":"Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006:CD003727.","DOI":"10.1002\/14651858.CD003727.pub3"},{"key":"1078_CR58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00002018-200022010-00006","volume":"22","author":"CH Miller","year":"2000","unstructured":"Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000;22:73\u201381.","journal-title":"Drug Saf"},{"key":"1078_CR59","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mds.870040208","volume":"4","author":"RE Burke","year":"1989","unstructured":"Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4:157\u201375.","journal-title":"Mov Disord"},{"key":"1078_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0010-440X(75)90019-X","volume":"16","author":"T Van Putten","year":"1975","unstructured":"Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975;16:43\u20137.","journal-title":"Compr Psychiatry"},{"key":"1078_CR61","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders. 5th ed., text revision","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., text revision. Washington, DC: American Psychiatric Association Publishing; 2022."},{"key":"1078_CR62","doi-asserted-by":"crossref","unstructured":"Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY). 2013;3:tre-03-161-4138-1.","DOI":"10.5334\/tohm.165"},{"key":"1078_CR63","doi-asserted-by":"crossref","unstructured":"Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2022;28:4\u201314.","DOI":"10.1017\/S1092852922000992"},{"key":"1078_CR64","doi-asserted-by":"crossref","unstructured":"Caroff SN, Citrome L, Meyer J, Sajatovic M, Goldberg JF, Jain R, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81:19cs12983.","DOI":"10.4088\/JCP.19cs12983"},{"key":"1078_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","volume":"389","author":"R Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67\u201375.","journal-title":"J Neurol Sci"},{"key":"1078_CR66","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2147\/NDT.S196541","volume":"15","author":"SN Caroff","year":"2019","unstructured":"Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785\u201394.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1078_CR67","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","volume":"6","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6:134\u201344.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"1078_CR68","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","volume":"178","author":"YB Joshi","year":"2021","unstructured":"Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic medication burden-associated cognitive impairment in schizophrenia. Am J Psychiatry. 2021;178:838\u201347.","journal-title":"Am J Psychiatry"},{"key":"1078_CR69","unstructured":"Trihexyphenidyl hydrochloride tablets. Prescribing information. Kothur-509 228, AP India: Natco Pharma Ltd; 2010."},{"key":"1078_CR70","unstructured":"Benztropine tablets. Prescribing information. Livonia: Major Pharmaceuticals; 2017."},{"key":"1078_CR71","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1124\/jpet.116.239160","volume":"361","author":"DE Grigoriadis","year":"2017","unstructured":"Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"1078_CR72","unstructured":"INGREZZA\u00ae (valbenazine) capsules. Prescribing information. San Diego: Neurocrine Biosciences, Inc.; 2023."},{"key":"1078_CR73","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","volume":"174","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476\u201384.","journal-title":"Am J Psychiatry"},{"key":"1078_CR74","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/JCP.0000000000001111","volume":"39","author":"SR Marder","year":"2019","unstructured":"Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39:620\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"1078_CR75","unstructured":"Austedo (deutetrabenazine) tablets and Austedo XR (deutetrabenazine) extended-release tablets. Prescribing information. Parsippany: Teva Pharmaceuticals USA, Inc.; 2023."},{"key":"1078_CR76","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595\u2013604.","journal-title":"Lancet Psychiatry"},{"key":"1078_CR77","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003\u201310.","journal-title":"Neurology"},{"key":"1078_CR78","first-page":"1317","volume":"90","author":"HH Fernandez","year":"2019","unstructured":"Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90:1317\u201323.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1078_CR79","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/070674371205700810","volume":"57","author":"RE Nielsen","year":"2012","unstructured":"Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57:512\u20138.","journal-title":"Can J Psychiatry"},{"key":"1078_CR80","volume-title":"Movement disorder emergencies: diagnosis and treatment","author":"SN Caroff","year":"2022","unstructured":"Caroff SN, Mann SC, Sullivan KA, Campbell EC. Neuroleptic malignant syndrome. In: Frucht SJ, editor. Movement disorder emergencies: diagnosis and treatment. 3rd ed. Cham: Humana Press; 2022.","edition":"3"},{"key":"1078_CR81","doi-asserted-by":"publisher","first-page":"938-a","DOI":"10.1176\/appi.ps.51.7.938-a","volume":"51","author":"SN Caroff","year":"2000","unstructured":"Caroff SN, Mann SC, Campbell EC. Risk of fatal heatstroke after hospitalization. Psychiatr Serv. 2000;51:938-a.","journal-title":"Psychiatr Serv"},{"key":"1078_CR82","doi-asserted-by":"publisher","first-page":"19177","DOI":"10.1038\/s41598-023-41347-3","volume":"13","author":"A Davariashtiyani","year":"2023","unstructured":"Davariashtiyani A, Taherkhani M, Fattahpour S, Vitousek S. Exponential increases in high-temperature extremes in North America. Sci Rep. 2023;13:19177.","journal-title":"Sci Rep"},{"key":"1078_CR83","doi-asserted-by":"crossref","unstructured":"Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry. 1990;156:412.","DOI":"10.1192\/bjp.156.3.412"},{"key":"1078_CR84","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1177\/0269881112447988","volume":"26","author":"JE Desmarais","year":"2012","unstructured":"Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol (Oxford, England). 2012;26:1167\u201374.","journal-title":"J Psychopharmacol (Oxford, England)."},{"key":"1078_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/BF00432269","volume":"61","author":"TA Stern","year":"1979","unstructured":"Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology. 1979;61:261\u20132.","journal-title":"Psychopharmacology"},{"key":"1078_CR86","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1176\/ajp.143.6.706","volume":"143","author":"RS Winslow","year":"1986","unstructured":"Winslow RS, Stillner V, Coons DJ, Robison MW. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. Am J Psychiatry. 1986;143:706\u201310.","journal-title":"Am J Psychiatry"},{"key":"1078_CR87","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00004714-198706000-00008","volume":"7","author":"WF Boyer","year":"1987","unstructured":"Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol. 1987;7:164\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"1078_CR88","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0091270006292126","volume":"46","author":"RM Carnahan","year":"2006","unstructured":"Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481\u20136.","journal-title":"J Clin Pharmacol"},{"key":"1078_CR89","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"JL Rudolph","year":"2008","unstructured":"Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508\u201313.","journal-title":"Arch Intern Med"},{"key":"1078_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-019-02795-x","volume":"76","author":"S Ali","year":"2020","unstructured":"Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76:319\u201335.","journal-title":"Eur J Clin Pharmacol"},{"key":"1078_CR91","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fphar.2020.00570","volume":"11","author":"K Graves-Morris","year":"2020","unstructured":"Graves-Morris K, Stewart C, Soiza RL, Taylor-Rowan M, Quinn TJ, Loke YK, et al. The prognostic value of anticholinergic burden measures in relation to mortality in older individuals: a systematic review and meta-analysis. Front Pharmacol. 2020;11:570.","journal-title":"Front Pharmacol"},{"key":"1078_CR92","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40801-021-00256-5","volume":"8","author":"D Mehdizadeh","year":"2021","unstructured":"Mehdizadeh D, Hale M, Todd O, Zaman H, Marques I, Petty D, et al. Associations between anticholinergic medication exposure and adverse health outcomes in older people with frailty: a systematic review and meta-analysis. Drugs Real World Outcomes. 2021;8:431\u201358.","journal-title":"Drugs Real World Outcomes."},{"key":"1078_CR93","doi-asserted-by":"publisher","first-page":"204209862110166","DOI":"10.1177\/20420986211016645","volume":"12","author":"C Stewart","year":"2021","unstructured":"Stewart C, Taylor-Rowan M, Soiza RL, Quinn TJ, Loke YK, Myint PK. Anticholinergic burden measures and older people\u2019s falls risk: a systematic prognostic review. Ther Adv Drug Saf. 2021;12:20420986211016644.","journal-title":"Ther Adv Drug Saf."},{"key":"1078_CR94","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40266-020-00806-6","volume":"37","author":"J Reinold","year":"2020","unstructured":"Reinold J, Schafer W, Christianson L, Barone-Adesi F, Riedel O, Pisa FE. Anticholinergic burden and fractures: a systematic review with methodological appraisal. Drugs Aging. 2020;37:885\u201397.","journal-title":"Drugs Aging"},{"issue":"65\u201373","key":"1078_CR95","volume":"22","author":"A Egberts","year":"2021","unstructured":"Egberts A, Moreno-Gonzalez R, Alan H, Ziere G, Mattace-Raso FUS. Anticholinergic drug burden and delirium: a systematic review. J Am Med Dir Assoc. 2021;22(65\u201373): e4.","journal-title":"J Am Med Dir Assoc"},{"key":"1078_CR96","first-page":"CD013540","volume":"5","author":"M Taylor-Rowan","year":"2021","unstructured":"Taylor-Rowan M, Edwards S, Noel-Storr AH, McCleery J, Myint PK, Soiza R, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5:CD013540.","journal-title":"Cochrane Database Syst Rev"},{"key":"1078_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1315","volume":"361","author":"K Richardson","year":"2018","unstructured":"Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361: k1315.","journal-title":"BMJ"},{"key":"1078_CR98","first-page":"80","volume":"33","author":"AM Lupu","year":"2021","unstructured":"Lupu AM, MacCamy KL, Gannon JM, Brar JS, Chengappa KNR. Less is more: deprescribing anticholinergic medications in persons with severe mental illness. Ann Clin Psychiatry. 2021;33:80\u201392.","journal-title":"Ann Clin Psychiatry"},{"key":"1078_CR99","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/2045125314553611","volume":"4","author":"JE Desmarais","year":"2014","unstructured":"Desmarais JE, Beauclair L, Annable L, B\u00e9langer MC, Kolivakis TT, Margolese HC. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014;4:257\u201367.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1078_CR100","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11096-019-00784-9","volume":"41","author":"N Ailabouni","year":"2019","unstructured":"Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm. 2019;41:167\u201378.","journal-title":"Int J Clin Pharm"},{"key":"1078_CR101","first-page":"11","volume":"48","author":"RH Howland","year":"2010","unstructured":"Howland RH. Potential adverse effects of discontinuing psychotropic drugs. Part 1: adrenergic, cholinergic, and histamine drugs. J Psychosoc Nurs Ment Health Serv. 2010;48:11\u20134.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"1078_CR102","first-page":"606","volume":"45","author":"J de Leon","year":"1994","unstructured":"de Leon J, Canuso C, White AO, Simpson GM. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp Community Psychiatry. 1994;45:606\u20137.","journal-title":"Hosp Community Psychiatry"},{"key":"1078_CR103","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pnpbp.2010.08.030","volume":"35","author":"S Ogino","year":"2011","unstructured":"Ogino S, Miyamoto S, Tenjin T, Kitajima R, Ojima K, Miyake N, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:78\u201383.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1078_CR104","doi-asserted-by":"publisher","first-page":"e1270","DOI":"10.4088\/JCP.16m11269","volume":"78","author":"AM Lupu","year":"2017","unstructured":"Lupu AM, Clinebell K, Gannon JM, Ellison JC, Chengappa KNR. Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. J Clin Psychiatry. 2017;78:e1270\u20135.","journal-title":"J Clin Psychiatry"},{"key":"1078_CR105","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0196-0644(84)80613-7","volume":"13","author":"KA Corre","year":"1984","unstructured":"Corre KA, Niemann JT, Bessen HA. Extended therapy for acute dystonic reactions. Ann Emerg Med. 1984;13:194\u20137.","journal-title":"Ann Emerg Med"},{"key":"1078_CR106","unstructured":"Kowalski JM. Medication-induced dystonic reactions. 2022. https:\/\/emedicine.medscape.com\/article\/814632-overview. Accessed 4 Apr 2023."},{"key":"1078_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.775","volume":"9","author":"SC Trenaman","year":"2021","unstructured":"Trenaman SC, Bowles SK, Andrew MK, Goralski K. The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharmacol Res Perspect. 2021;9: e00775.","journal-title":"Pharmacol Res Perspect"},{"key":"1078_CR108","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.cger.2022.05.007","volume":"38","author":"E Roh","year":"2022","unstructured":"Roh E, Cota E, Lee JP, Madievsky R, Eskildsen MA. Polypharmacy in nursing homes. Clin Geriatr Med. 2022;38:653\u201366.","journal-title":"Clin Geriatr Med"},{"key":"1078_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255642","volume":"16","author":"EH Young","year":"2021","unstructured":"Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS ONE. 2021;16: e0255642.","journal-title":"PLoS ONE"},{"issue":"71","key":"1078_CR110","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"2023","author":"2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel.","year":"2023","unstructured":"2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;2023(71):2052\u201381.","journal-title":"J Am Geriatr Soc"},{"key":"1078_CR111","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/gerona\/glaa057","volume":"75","author":"A Edjolo","year":"2020","unstructured":"Edjolo A, Dartigues JF, Peres K, Proust-Lima C. Heterogeneous long-term trajectories of dependency in older adults: the PAQUID cohort, a population-based study over 22 years. J Gerontol A Biol Sci Med Sci. 2020;75:2396\u2013403.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1078_CR112","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12991-022-00418-x","volume":"21","author":"LM Ward","year":"2022","unstructured":"Ward LM, Cooper SA, Henderson A, Stanley B, Greenlaw N, Pacitti C, et al. A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study. Ann Gen Psychiatry. 2022;21:41.","journal-title":"Ann Gen Psychiatry"},{"key":"1078_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046630","volume":"11","author":"N Thayer","year":"2021","unstructured":"Thayer N, White S, Islam J, Jones W, Kenzie S, Kullu R. Reducing risks associated with medicines and lifestyle in a residential care population with intellectual disabilities: evaluation of a pharmacy review initiative in England. BMJ Open. 2021;11: e046630.","journal-title":"BMJ Open"},{"key":"1078_CR114","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/WAD.0000000000000513","volume":"36","author":"A Maltais","year":"2022","unstructured":"Maltais A, Simard M, Vedel I, Sirois C. Changes in polypharmacy and psychotropic medication use after diagnosis of major neurocognitive disorders: a population-based study in Quebec, Canada. Alzheimer Dis Assoc Disord. 2022;36:222\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1078_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2021.06.004","volume":"151","author":"K Wang","year":"2021","unstructured":"Wang K, Alan J, Page AT, Dimopoulos E, Etherton-Beer C. Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review. Maturitas. 2021;151:1\u201314.","journal-title":"Maturitas"},{"key":"1078_CR116","first-page":"580","volume":"42","author":"W Land","year":"1991","unstructured":"Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. Hosp Community Psychiatry. 1991;42:580\u20131.","journal-title":"Hosp Community Psychiatry"},{"key":"1078_CR117","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09540261.2016.1235017","volume":"29","author":"TN Collins","year":"2017","unstructured":"Collins TN, Avondoglio JB, Terry LM. Correctional psychopharmacology: pitfalls, challenges, and victories of prescribing in a correctional setting. Int Rev Psychiatry. 2017;29:34\u201344.","journal-title":"Int Rev Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01078-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01078-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T09:12:46Z","timestamp":1711703566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01078-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01078-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"27 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The expert roundtable referenced in this article was supported by Neurocrine Biosciences, Inc. (San\u00a0Diego, CA). Writing and editorial assistance from Prescott Medical Communications Group (Chicago, IL) and open access funding were also provided by Neurocrine Biosciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N.V.A. has received consulting honoraria from Neurocrine Biosciences and research support from the National Institutes of Health and the Parkinson\u2019s Disease Foundation. S.N.C. has served as a consultant to Neurocrine Biosciences, Teva Pharmaceuticals, Osmotica Pharmaceuticals, and Dispersol Technologies. S.N.C. has received separate research grants from Neurocrine Biosciences, Osmotica Pharmaceuticals, and Eagle Pharmaceuticals. L.C. has received consulting fees from: AbbVie\/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, Inmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo\/Sunovion, Supernus, Teva, University of Arizona, Vanda, Wells Fargo, and one-off ad hoc consulting for individuals\/entities conducting marketing, commercial, or scientific scoping research; is a speaker for: AbbVie\/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and universities and professional organizations\/societies; owns stocks (small number of shares of common stock) in: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago, stock options: Reviva; and receives royalties\/publishing income from: Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-date), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), and Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics) J.C. has been a consultant or advisor to Neurocrine Biosciences, Sunovion, Takeda, AstraZeneca, Otsuka, Janssen, Actavis (now AbbVie), Lundbeck, and Alkermes. R.S.M. has received research support from the Global Alliance for Chronic Diseases, Canadian Institutes of Health Research, National Natural Science Foundation of China-Mental Health Team, and the Milken Institute, and speaker\/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine Biosciences, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris Pharma, Sanofi, Eisai, Intra-Cellular Therapies, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life Sciences. R.S.M. is the CEO of Braxia Scientific Corp. J.M.M. has served as a speaker or advisor for Alkermes, AbbVie, Axsome, BioXcel, Cerevel, Intra-Cellular Therapies, Karuna, Neurocrine Biosciences, Noven Pharmaceuticals, Otsuka America, Inc., Relmada, Sunovion, and Teva Pharmaceuticals. A.P. has received consultant or speaker fees from Neurocrine Biosciences, Avanir Pharmaceuticals, Acadia Pharmaceuticals, Otsuka, Allergan (now AbbVie), Teva Pharmaceuticals, AstraZeneca, and Takeda. J.M.S. has received consulting fees from Neurocrine Biosciences. K.F., R.M., and S.A.C. are full-time employees of Neurocrine Biosciences, Inc. L.L. is a former full-time employee of Neurocrine Biosciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests\/Competing Interests"}},{"value":"N.V.A. and S.N.C. were involved in the conception and planning of the expert roundtable discussion. N.V.A., S.N.C., L.C., J.C., R.S.M., J.M.M., A.P., and J.M.S. participated in the\u00a0expert roundtable featured in\u00a0this article. All authors contributed to the development of the\u00a0manuscript and provided critical reviews of multiple drafts. All authors approved the final\u00a0draft for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}